IP Library › Granted Patent US 7,799,807

Granted Patent B2

US 7,799,807 · App. 11/386,058 · Granted Sep 21, 2010

Therapeutic agents useful for treating pain

Assignee: Purdue Pharma L.P.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,799,807
App. No.: 11/386,058
Granted: Sep 21, 2010
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention discloses compounds of formula: where Ar 1 , Ar 2 , X, R 1 , R 2 , R 3 , m, and n are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.

Claims (211)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(b) —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups; or

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each R 5 is independently —CN, —OH, —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ;

each R 6 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —CN, —OH, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ;

each R 7 is independently —H, —(C 1 -C 6 )alkenyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, —C(halo) 3 , —CH(halo) 2 , or CH 2 (halo);

each R 8 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —C(halo) 3 , —CH(halo) 2 , —CH 2 (halo), —CN, —OH, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ;

each halo is independently —F, —Cl, —Br, or —I;

n is an integer ranging from 1 to 3; and

o is an integer ranging from 0 to 4.

2. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

n is an integer ranging from 0 to 3;

o is an integer ranging from 0 to 4;

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each R 8 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH(halo) 2 , —CH 2 (halo), —CN, —OH, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ; and

each halo is independently —F, —Cl, —Br, or —I.

3. A compound of formula:

or a pharmaceutically acceptable salt thereot wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

n is an integer ranging from 0 to 3;

r is an integer ranging from 0 to 5;

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(b) —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups; or

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each R 8 is independently —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkenyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH(halo) 2 , —CH 2 (halo), —CN, —OH, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ; and

each halo is independently —F, —Cl, —Br, or —I.

4. The compound of claim 3 , wherein:

X is O;

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br; and

n is 1 or 2.

5. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 2 and a pharmaceutically acceptable carrier or excipient.

6. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

7. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

each R 2 is indepedently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each halo is independently —F, —Cl, —Br, or —I.

each halo is independently —F, —Cl, —Br, or —I;

n is an integer ranging from 0 to 3; and

s is an integer ranging from 0 to 4.

8. The compound of claim 7 , wherein:

X is O;

R 1 is —CH 3 , —CF 3 , —Cl, —Br, —I, or —F;

n is 1 or 2;

(R 8 ) a is —H; and

(R 8 ) is —H, —CH 3 , —OCH 3 , —CF 3 , —OCF 3 , —OCH 2 CH 3 , iso-propyl, tert-butyl, —Cl, —Br, —I, or —F.

9. The compound of claim 8 , wherein R 1 is —CH 3 , —CF 3 , —F, or —Cl, and (R 8 ) b is —Cl, —F, —CF 3 , —OCF 3 , or tert-butyl.

10. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 2 .

11. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 .

12. The compound of claim 2 , wherein o is 0, 1, or 2 and an R 8 group, when present, is -halo or —(C 1 -C 6 )alkyl.

13. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 3 and a pharmaceutically acceptable carrier or excipient.

14. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 3 .

15. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 1 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

16. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 2 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

17. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 3 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

18. The compound of claim 8 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

19. The compound of claim 18 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

20. The compound of claim 9 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

21. The compound of claim 20 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

22. The compound of claim 2 , wherein:

X is 0;

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br; and

n is 1 or 2.

23. The compound of claim 22 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

24. The compound of claim 23 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

25. The compound of claim 12 , wherein:

X is 0;

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br; and

n is 1 or 2.

26. The compound of claim 25 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

27. The compound of claim 26 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

28. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

n is the integer 1 or 2;

o is an integer ranging from 0 to 4;

R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups;

each R 8 is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, —(C 3 -C 8 )cycloalkenyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, —CH(halo) 2 , —CH 2 (halo), —CN, —OH, -halo, —N 3 , —NO 2 , —N(R 7 ) 2 , —CH═NR 7 , —NR 7 OH, —OR 7 , —COR 7 , —C(O)OR 7 , —OC(O)R 7 , —OC(O)OR 7 , —SR 7 , —S(O)R 7 , or —S(O) 2 R 7 ; and

each halo is independently —F, —Cl, —Br, or —I.

29. The compound of claim 28 , wherein:

X is 0; and

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br. -

30. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is o or

R 1 is -halo —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

n is the integer 1 or 2;

o is 0, 1, or 2;

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

an R 8 , group when present is -halo or —(C 1 -C 6 )alkyl; and

each halo is independently —F, —Cl, —Br, or —I.

31. The compound of claim 30 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

32. The compound of claim 30 , wherein:

X is 0; and

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br.

33. The compound of claim 32 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

34. The compound of claim 33 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

35. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

n is the integer 1 or 2;

r is an integer ranging from 0 to 5;

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each halo is independently —F, —Cl, —Br, or —I.

36. The compound of claim 35 , wherein:

X is 0; and

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br.

37. The compound of claim 36 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

38. The compound of claim 37 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

39. The compound of claim 35 , wherein r is 0, 1, or 2, each R 8 , when present, is independently tert-butyl, iso-butyl, sec-butyl, iso-propyl, -cyclohexyl, tert-butoxy, iso-propoxy, —CF 3 , —OCF 3 , —Cl, or —F, and an R 8 group, when present, is substituted at the 4-position of Ar 2 .

40. The compound of claim 39 , wherein:

X is 0; and

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br.

41. The compound of claim 40 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

42. The compound of claim 41 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

43. The compound of claim 1 , wherein:

X is O;

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br; and

n is 1 or 2.

44. The compound of claim 43 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

45. The compound of claim 44 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

46. The compound of claim 43 , wherein o is 0, 1, or 2 and an R 8 group when present is -halo or —(C 1 -C 6 )alkyl.

47. The compound of claim 46 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

48. The compound of claim 47 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

49. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 7 and a pharmaceutically acceptable carrier or excipient.

50. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 7 .

51. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 7 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

52. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is O or S;

R 1 is -halo, —CH 3 , —C(halo) 3 , —CH(halo) 2 , or —CH 2 (halo);

each R 2 is independently:

(a) -halo, —OH, —NH 2 , —CN or —NO 2 ;

(c) -phenyl, -naphthyl, —(C 14 )aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R 6 groups;

each halo is independently —F, —Cl, —Br, or —I.

n is 0; and

o is an integer ranging from 0 to 4.

53. The compound of claim 52 , wherein:

X is 0; and

R 1 is —CH 3 , —CF 3 , —F, —Cl, or —Br.

54. The compound of claim 53 , wherein o is 0, 1, or 2 and an R 8 group when present is -halo or —(C 1 -C 6 )alkyl.

55. The compound of claim 4 , wherein r is 0, 1, or 2, each R 8 , when present, is independently tert-butoxy, iso-propoxy, —CF 3 , —OCF 3 , —Cl, or —F, and an R 8 group, when present, is substituted at the 4-position of Ar 2 .

56. The compound of claim 4 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

57. The compound of claim 56 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

58. The compound of claim 55 , wherein n is 1 and R 2 is —(C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, —(C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R 5 groups.

59. The compound of claim 58 , wherein R 2 is —(C 1 -C 10 )alkyl which is substituted with two R 5 groups.

60. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 35 and a pharmaceutically acceptable carrier or excipient.

61. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 35 .

62. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 35 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

63. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 28 and a pharmaceutically acceptable carrier or excipient.

64. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 28 .

65. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 28 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

66. A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 30 and a pharmaceutically acceptable carrier or excipient.

67. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 30 .

68. An in vitro method for inhibiting VR1 function in a cell comprising:

contacting a cell expressing VR1 in vitro with a compound of claim 30 , or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce calcium ion mobilization into said cell treated with an activator of VR1 as compared to said cell expressing VR1 in vitro treated with an activator of VR1 and not contacted with said compound.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2008

From: EURO-CELTIQUE S.A.

To: PURDUE PHARMA L.P.

Reel/Frame 020311/0279 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2006

From: SUN, QUN

To: EURO-CELTIQUE S.A.

Reel/Frame 018161/0366 →

Continuity (3)

Continuation PCTUS200403082400 · Sep 21, 2004

Provisional Application 6050467900 · Sep 22, 2003

Related Publication 20060235022A1 · Oct 19, 2006